CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that the Company received a staff determination letter (the “Letter”) on Feb. 27, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the determination of the Nasdaq staff (the “Staff”) to delist the Company’s securities from The Nasdaq Global Market due to non-compliance with the minimum USD $15 million Market Value of Publicly Held Shares (“MVPHS”) requirement as set forth in Nasdaq Listing Rule 5450(b)(2)(C). The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s securities.

Read more at globenewswire.com